Pfizer will advance Western Oncolytics’ novel preclinical oncolytic vaccinia virus, WO-12, the companies report, through a collaboration whose value was not disclosed.

Pfizer and Western Oncolytics said their collaboration in oncolytic virus development will add another novel technology platform to Pfizer’s cancer vaccine efforts, as well as to its immuno-oncology portfolio.

“Our goal is to combine WO-12 with our portfolio of promising investigational immunotherapies to explore how these novel combinations could help further enhance the body’s immune response in fighting cancer cells,” James Merson, Ph.D., CSO, vaccine immunotherapeutics at Pfizer, said in a statement.